29 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
19 Jan 24
Regulation FD Disclosure
2:33pm
to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com/home.
Investor Contact:
Colin
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
24 Jul 23
Regulation FD Disclosure
4:26pm
of investors while helping to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
19 May 23
Regulation FD Disclosure
1:41pm
” opens the door to reach a much broader and diverse set of investors while helping to strengthen overall communications, transparency, and engagement
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
4:01pm
-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency
8-K
EX-99.1
cy8gtckgv24mv
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
424B5
mjnts8x8h9i12ye4bn
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
edpuu 5ebq0
25 Apr 22
Prospectus supplement
5:02pm
424B3
m502e
7 Apr 22
Prospectus supplement
4:46pm
S-3
mvtd 2wko
4 Feb 22
Shelf registration
4:36pm
8-K/A
EX-99.2
ixzbwn q3j6tzj4j5d
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.1
lfqiu1
22 Dec 21
Audited Financial Statements
12:00am
10-K
rmy6 s5qeqsv2h2t95g1
24 Sep 21
Annual report
7:31am
424B3
n7afrzqg
22 Jul 21
Prospectus supplement
10:27am
424B3
j5981g yiqt
16 Mar 21
Prospectus supplement
12:00am